Evidence map›Paper›PMID 35241529›Full record

ArticleIn vivo (Athens, Greece)

Secretory Phospholipase A2 Digital Expression Analysis in Colon Adenocarcinoma.

Evangelos Falidas, Eirini Kitsiouli, Despoina Spyropoulou, Evangelos Tsiambas, Asimina Kalogirou, George Tsouvelas, Stylianos Papadopoulos, Michail Mitsis, Marilena Lekka, Sofianiki Mastronikoli and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Evangelos FalidasDepartment of Surgery, Halkida General Hospital, Halkida, Greece.
Eirini KitsiouliLaboratory of Biochemistry, Chemistry Department, University of Ioannina, Ioannina, Greece.
Despoina SpyropoulouDepartment of Radiation Oncology, Medical School, University of Patras, Patras, Greece.
Evangelos TsiambasDepartment of Cytology, 417 VA (NIMTS) Hospital, Athens, Greece; tsiambasecyto@yahoo.gr.
Asimina KalogirouDepartment of Pathology, Halkida General Hospital, Halkida, Greece.
George TsouvelasDepartment of Nursing, University of West Attica, Athens, Greece.
Stylianos PapadopoulosLaboratory of Biochemistry, Chemistry Department, University of Ioannina, Ioannina, Greece.
Michail MitsisDepartment of Surgery, University Hospital of Ioannina, University of Ioannina, Ioannina, Greece.
Marilena LekkaLaboratory of Biochemistry, Chemistry Department, University of Ioannina, Ioannina, Greece.
Sofianiki MastronikoliBrighton and Sussex Medical School, Brighton, U.K.
Dimitrios PeschosDepartment of Physiology, Medical School, University of Ioannina, Ioannina, Greece.
Odysseas Dimas2 Department of Internal Medicine, "Gennimatas" General Hospital, Athens, Greece.
Konstantinos VlachosDepartment of Surgery, University Hospital of Ioannina, University of Ioannina, Ioannina, Greece.
University of Ioannina · GRGeneral Hospital of Attica · GRUniversity Hospital of Ioannina · GRGeneral Hospital of Athens G. Genimatas · GRNIMTS Hospital · GRUniversity of Patras · GRUniversity of West Attica · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimPhospholipases A2 represent a family of enzymes that regulate the metabolism of phospholipids by hydrolyzing them into fatty acids. Secretory phospholipase A2 (SPLA2) catalyzes the calcium-dependent 2-acyl groups hydrolysis to produce 3-sn-phosphoglycerides. This study aimed to investigate SPLA2 expression in colon adenocarcinoma (CA). MATERIALS AND

methodsThirty (n=30) formalin-fixed, paraffin-embedded primary CA tissue sections were used and analyzed. Immunohistochemistry was performed using an anti-SPLA2 antibody. Digital image analysis was also implemented for evaluating objectively the corresponding protein expression levels.

resultsIncreased SPLA2 protein expression (high & moderate immunostaining levels) was observed in 23/30 (76.6%) cases, whereas 7/30 (23.4%) CA tissues demonstrated low protein levels. High expression levels were detected in 9/30 (30%) cases. SPLA2 overall expression was strongly associated with tumor diameter (p=0.004), whereas other statistically significant associations were not observed (stage: p=0.971, inflammatory infiltration: p=0.795; carcinoma location: p=0.340; differentiation grade: p=0.748; sex: p=0.369; ulceration: p=0.433).

conclusionSPLA2 over-expression is observed in significant subsets of CAs correlating with advanced tumor growth progression (increased diameter). SPLA2 seems to influence endogenous cell responses by its crucial enzymatic activity and can potentially be a biomarker for monitoring CA patients.

Indexed as

Colonic NeoplasmsPhospholipases A2, SecretoryFatty AcidsHumansImmunohistochemistryPhospholipidsFatty AcidsPhospholipases A2, SecretoryPhospholipidsCarcinomacolonimmunohistochemistryoxidative stressphospholipase

Identifiers

PMID35241529
PMCPMC8931885
OpenAlexW4214809791

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.